Investing
Day Trader Alerts (AMGN, NVS, MSCS, DRYS, ARYX, XNPT, ARNA, BPZ)
Published:
Last Updated:
These are some of the top stocks for day traders and active traders to watch based on pre-market and after-hours volume activity with links to more detailed price and volume analysis on each situation at VSInvestor.com:
- Amgen Inc. (AMGN) is up about 13% on positive Phase III trial results; Novartis Inc. (NYSE: NVS) may be affected negatively.
- MSC Software Corp. (Nasdaq: MSCS) shares are up as Symphony Technology placed a bid on the company for $360 million.
- DryShips Inc. (Nasdaq: DRYS) scored a Credit Suisse upgrade on the stock with close a 5% gain.
- ARYx Therapeutics Inc. (Nasdaq: ARYX) is getting halved after the company’s experimental anticoagulant failed in a late-stage study.
- xenoport Inc. (NASDAQ: XNPT) shares were down strongly after hours on a secondary offering. Ditto on Arena Pharmaceuticals Inc. (NASDAQ: ARNA).
- BPZ Resources Inc. (NYSE: BPZ) is rising after it announced a credit line that will be used to help it fund projects in Peru.
-The 24/7 Wall St. Team
Want to Retire Early? Start Here (Sponsor)
Want retirement to come a few years earlier than you’d planned? Or are you ready to retire now, but want an extra set of eyes on your finances?
Now you can speak with up to 3 financial experts in your area for FREE. By simply clicking here you can begin to match with financial professionals who can help you build your plan to retire early. And the best part? The first conversation with them is free.
Click here to match with up to 3 financial pros who would be excited to help you make financial decisions.
Have questions about retirement or personal finance? Email us at [email protected]!
By emailing your questions to 24/7 Wall St., you agree to have them published anonymously on a673b.bigscoots-temp.com.
By submitting your story, you understand and agree that we may use your story, or versions of it, in all media and platforms, including via third parties.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
